EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies

Jordan Wilk iD, Varun Aggarwal iD, Mike Pauley, Diane Corey, Daniela J Conrado, Karthik Lingineni, Juan Francisco Morales iD, Deok Yong Yoon iD, Yi Zhang, Zihan Cui, Jackson Burton iD, Jane Larkindale iD und 7 weitere

CPT: Pharmacometrics & Systems Pharmacology · 2025-11 · 14 (11) · 1787-1796

DOI: 10.1002/psp4.13281 ↗

Kurz gefasst

Fallbericht in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 27.11.2024. Verfasst von Jordan Wilk und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Computer Simulation, Muscular Dystrophy, Duchenne, Research Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, NCATS NIH HHS, FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD), a rare pediatric disease, presents numerous challenges when designing clinical trials, mainly due to the scarcity of available trial participants and the heterogeneity of disease progression. A quantitative clinical trial simulator (CTS) has been developed based on previously published five disease progression models describing each of the longitudinal changes in the velocity at which individuals can complete specified timed functional tests, frequently used as clinical trial efficacy endpoints (supine‐stand, 4‐stair climb, and 10 m walk/run test or 30‐foot walk/run test), as well as each of the longitudinal changes in forced vital capacity and North Star Ambulatory Assessment total score. The model‐based CTS allows researchers to optimize the selection of numerous trial parameters for designing trials for the five functional measures commonly used as endpoints in DMD clinical trials. This case report serves as a demonstration of the tool's functionality while providing an easy‐to‐follow guide for users to reference when preparing simulations of their own design. Two case studies, using input selection based on previous DMD clinical trials, provide realistic examples of how the tool can help optimize clinical trial design without the risk of decreasing statistical significance. This optimization allows researchers to mitigate the risk of designing trials that may be longer, larger, or more inclusive/exclusive than necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicComputer SimulationMuscular Dystrophy, DuchenneResearch DesignHumansDisease Progression

Autor:innen und Institutionen

  • Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.
  • Department of Mathematics, College of Sciences, University of Central Florida, Orlando, Florida, USA.
  • Critical Path Institute (C-Path), Tucson, Arizona, USA.
  • e-Quantify LLC, La Jolla, California, USA.
  • Novartis Pharmaceutical Corporation, Cambridge, Massachusetts, USA.
  • Biogen, Cambridge, Massachusetts, USA.

ORCID-Profile: Jordan Wilk, Varun Aggarwal, Juan Francisco Morales, Deok Yong Yoon, Jackson Burton, Jane Larkindale, Terina Martinez, Ramona Belfiore-Oshan, Sarah Kim

Förderung

  • NIAMS NIH HHS
  • NCATS NIH HHS
  • FDA HHS

Zitieren

APA

Wilk, J., Aggarwal, V., Pauley, M., Corey, D., Conrado, D. J., Lingineni, K., Morales, J. F., Yoon, D. Y., Zhang, Y., Cui, Z., Burton, J., Larkindale, J., Ma, S. C., Hovinga, C., Martinez, T., Romero, K., Belfiore-Oshan, R., Kim, S., & Duchenne Regulatory Science Consortium (D‐RSC) and the CINRG DNHS investigators (2025). A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies. CPT: Pharmacometrics & Systems Pharmacology, 14(11), 1787-1796. https://doi.org/10.1002/psp4.13281

Vancouver

Wilk J, Aggarwal V, Pauley M, Corey D, Conrado DJ, Lingineni K, et al. A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(11):1787-1796. doi:10.1002/psp4.13281

BibTeX
@article{Wilk2025,
  author = {Wilk, Jordan and Aggarwal, Varun and Pauley, Mike and Corey, Diane and Conrado, Daniela J and Lingineni, Karthik and Morales, Juan Francisco and Yoon, Deok Yong and Zhang, Yi and Cui, Zihan and Burton, Jackson and Larkindale, Jane and Ma, Shu Chin and Hovinga, Collin and Martinez, Terina and Romero, Klaus and Belfiore-Oshan, Ramona and Kim, Sarah and Duchenne Regulatory Science Consortium (D‐RSC) and the CINRG DNHS investigators, Duchenne Regulatory Science Consortium (D‐RSC) and the CINRG DNHS investigators},
  title = {A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  volume = {14},
  number = {11},
  pages = {1787--1796},
  doi = {10.1002/psp4.13281}
}
Kostenlos starten →